Bronchogen Injectable
Bronchogen 20 mg contains the AEDL tetrapeptide (Ala-Glu-Asp-Leu), a synthetic bioregulator developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue research. It belongs to the Khavinson short peptide class, which is investigated for proposed epigenetic mechanisms involving direct interaction with DNA and modulation of gene expression in target tissues.
In research contexts, Bronchogen is studied for its potential effects on bronchial epithelium through regulation of differentiation factors including NKX2-1, SCGB1A1, and FOXA1/2. Preclinical animal models have investigated its effects on lung morphology and bronchoalveolar fluid composition following inflammatory and toxic insults. The proposed mechanism involves sequence-specific DNA binding, with Bronchogen showing preferential affinity for CTG-containing sequences.
In bodybuilding and respiratory health contexts, Bronchogen is referenced anecdotally for supporting lung function and recovery from respiratory stress. However, all published research originates from Russian institutions, and no Western clinical trials or independent replications have been conducted. Such use falls outside any approved indication, and Bronchogen has no FDA-approved human product.
Research Properties of Bronchogen 20 mg
- AEDL tetrapeptide sequence (Ala-Glu-Asp-Leu)
- Proposed epigenetic modulation of bronchial epithelial gene expression
- Investigated for effects on NKX2-1, SCGB1A1, and FOXA1/2 differentiation factors
- Lyophilized powder format for extended stability
- 20 mg per vial for research applications
AEDL Tetrapeptide Bioregulator
Bronchogen belongs to the Khavinson bioregulator class, a family of ultrashort peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology for proposed tissue-specific regulatory effects. The AEDL sequence was identified from bronchial tissue extracts, suggesting a possible affinity for respiratory epithelium.
The proposed mechanism involves direct interaction with DNA and core histones after cellular penetration. Khavinson peptides are thought to bind to specific promoter regions, modulating chromatin accessibility and enabling transcription of genes associated with tissue homeostasis. Bronchogen has demonstrated preferential binding to CTG-containing DNA sequences in biophysical studies.
Research has investigated Bronchogen's effects on gene expression in bronchoepithelial cells, including upregulation of differentiation factors NKX2-1, SCGB1A1, SCGB3A2, FOXA1, and FOXA2. Animal models have reported normalization of goblet cell hyperplasia and restoration of ciliated cell populations following toxic lung damage.
Defining Characteristic
Epigenetic Mechanism of Action
Bronchogen is proposed to act through direct DNA interaction and gene expression modulation rather than cell-surface receptor binding. This epigenetic mechanism differs fundamentally from conventional respiratory medications (beta-agonists, anticholinergics, corticosteroids).
Bronchogen 20 mg vs Other Dragon Pharma Preparations
Dragon Pharma offers several Khavinson bioregulators and research peptides with different tissue targets. Cardiogen is the AEDP tetrapeptide targeting cardiac tissue, while Vesugen is the KED tripeptide for vascular endothelium. Testagen is the KEDG tetrapeptide investigated for endocrine regulation. These compounds share the Khavinson epigenetic paradigm but differ in their proposed tissue targets and amino acid sequences.
Typical Dosage Ranges
Common reference ranges for Bronchogen are derived primarily from Russian bioregulator protocols and community practices rather than controlled clinical trials. The standard pattern involves short cycles of 10–30 days with daily administration, followed by extended rest periods. Community sources reference injectable doses of 300–1000 mcg daily, while oral capsule protocols use higher milligram amounts due to lower bioavailability.
| Use Case |
Common Reference Range |
Frequency |
| Standard research cycle |
500–1000 mcg |
Daily for 20–30 days |
| Oral capsule protocol |
10–20 mg |
Daily for 10–20 days |
| Maintenance/longevity |
300–500 mcg |
20 days per quarter |
Reconstitution & Handling
Bronchogen 20 mg is supplied as a lyophilized powder requiring reconstitution. Bacteriostatic Water is commonly referenced for reconstituting research peptides. A 20 mg vial reconstituted with 2 mL yields a concentration of 10 mg/mL. Standard sterile technique and peptide handling practices should be observed.
Stacking & Research Considerations
In Khavinson bioregulator protocols, Bronchogen is sometimes referenced alongside other tissue-specific peptides. Cardiogen (cardiac tissue) and Vesugen (vascular endothelium) are the most commonly mentioned companions in cardiovascular-respiratory research contexts. However, no controlled studies have examined the safety or efficacy of these combinations.
Important
Individual Response Varies
The information above is for educational reference and does not constitute medical advice. Bronchogen has not been evaluated by the FDA for safety or efficacy.
Important Safety Information
No formal safety data exists for Bronchogen. All published research originates from a single Russian research program, and no independent Western replication or controlled human trials have been conducted. Pharmacokinetics, bioavailability, and optimal dosing in humans are completely uncharacterized.
Important
Non-Medical Use
Non-medical use of Bronchogen falls outside any approved indication. Product purity does not establish that non-medical use is safe or appropriate for an individual.
Potential Adverse Effects
Because Bronchogen is proposed to interact with DNA and modulate gene expression, theoretical risks include unintended effects on cellular regulation. No systematic human safety data are available to characterize common or rare adverse effects. Community sources report generally good tolerability, but this is anecdotal and not derived from controlled trials.
Conditions Requiring Medical Evaluation
Individuals with active respiratory emergencies, known hypersensitivity to peptide products, or pregnancy/breastfeeding status should exercise particular caution. No formal contraindication list exists for Bronchogen because it has not undergone Western regulatory review.
Monitoring Considerations
If Bronchogen is used in any research context, monitoring of respiratory function via spirometry (peak flow, FEV1) may be considered, though no standardized protocol exists. Laboratory testing of the product itself is separate from clinical monitoring of the individual.
Product Care
Storage & Handling
Store the lyophilized powder at -20°C for long-term storage, protected from light and moisture. Reconstitute only immediately before use and store at 2–8°C. Do not freeze reconstituted solution.
Keep all research peptides and injectable products out of the reach of children.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with no external product details. Products are supplied through the official Dragon Pharma distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is available
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Bronchogen 20 mg product, use the security code on the vial label and cross-check it on the official Dragon Pharma site. Original packaging and batch documentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Recommended Conditions
Store the lyophilized powder at -20°C for long-term storage, protected from light and moisture. The unopened vial should be kept under conditions that preserve the peptide's structural integrity until reconstitution.
Once reconstituted, Bronchogen solution should be stored at 2–8°C and used within a reasonable timeframe. Do not freeze reconstituted solution. Discard if solution becomes cloudy or develops particulate matter.
Keep out of reach of children. Follow proper handling practices for research peptides and use appropriate sterile technique during reconstitution.
Quick Reference
Do & Don't
- Do store lyophilized powder at -20°C for long-term storage
- Do protect from light and moisture
- Do store reconstituted solution at 2–8°C
- Don't freeze reconstituted solution
- Don't expose to excessive heat
- Don't use if powder appears discolored
What is Bronchogen 20 mg used for?
Bronchogen 20 mg is a research peptide supplied as a lyophilized powder. It contains the AEDL tetrapeptide, which is investigated for proposed epigenetic effects on bronchial epithelium gene expression. There is no FDA-approved human indication for Bronchogen.
How often should Bronchogen 20 mg be administered?
Common reference ranges for Bronchogen are derived from Russian bioregulator protocols rather than controlled trials. Standard patterns involve 500–1000 mcg daily for 20–30 days, followed by extended rest periods.
Does Bronchogen 20 mg require PCT?
Bronchogen is not an anabolic steroid and does not suppress endogenous testosterone production. Post-cycle therapy designed for steroid cycles is not applicable. Its proposed epigenetic mechanism is distinct from hormonal suppression.
What does Bronchogen do?
Bronchogen is proposed to penetrate cell nuclei and interact with DNA to modulate gene expression in bronchial epithelial tissues. Research has investigated its effects on differentiation factors including NKX2-1, SCGB1A1, and FOXA1/2. These mechanisms remain investigational and have not been independently validated.
How long does Bronchogen take to work?
No established onset timeline exists for Bronchogen in humans because no controlled trials have been completed. Its proposed epigenetic mechanism would theoretically involve gene expression changes that develop over days to weeks, with effects persisting after the peptide clears.
Is Bronchogen the best respiratory peptide?
No single respiratory peptide is universally superior. The Khavinson peptide class includes multiple compounds investigated for different tissue targets. Bronchogen's research focus on bronchial epithelium is distinct from other peptides in Dragon Pharma's catalog.
What is the difference between Bronchogen and Cardiogen?
Bronchogen (AEDL) and Cardiogen (AEDP) are both Khavinson tetrapeptides but have different amino acid sequences and proposed tissue targets. Bronchogen is associated with bronchial epithelium, while Cardiogen targets cardiac tissue.
What is the difference between Bronchogen and Vesugen?
Bronchogen (AEDL) and Vesugen (KED) are both Khavinson bioregulators but differ in sequence and proposed targets. Bronchogen targets bronchial tissue, while Vesugen targets vascular endothelium.
Is 20 mg of Bronchogen a lot?
20 mg is the total labeled content of the Bronchogen 20 mg vial. Because no standardized human dosage exists for this research peptide, the milligram amount cannot be classified as high or low relative to established protocols. Community protocols reference doses in the microgram range for injectable use.
What strength is Bronchogen 20 mg?
Bronchogen 20 mg by Dragon Pharma contains 20 mg of Bronchogen per vial as a lyophilized powder. The vial size is 2 mL. This is a research presentation.
Can Bronchogen be stacked with other peptides?
In Khavinson bioregulator protocols, Bronchogen is sometimes referenced alongside other tissue-specific peptides. Cardiogen and Vesugen are the most commonly mentioned companions. However, no controlled studies have examined the safety or efficacy of these combinations.
No reviews found
Please log in to write Bronchogen 20 mg review.
